Lance M. Hellman

Lance M. Hellman

Auto-generated profile, based on publicly available information

Lance M. Hellman

Department of Molecular and Cellular Biochemistry, University of Kentucky, Lexington, Kentucky, USA

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

17 September 2018 in Nature Chemical Biology
Verified
Journal Article
Closed access
PDF file
TRTimothy P. Riley
Timothy P. Riley
LHLance M. Hellman
Lance M. Hellman
MGMarvin H. Gee
Marvin H. Gee
JMJuan L. Mendoza
Juan L. Mendoza
JAJesus A. Alonso
Jesus A. Alonso
BBBrian M. Baker
Brian M. Baker

13 February 2014 in PLOS Computational Biology
Verified
Journal Article
Open access
PDF file
BPBrian G. Pierce
Brian G. Pierce
LHLance M. Hellman
Lance M. Hellman
MHMoushumi Hossain
Moushumi Hossain
NSNishant K. Singh
Nishant K. Singh
CKCraig W. Vander Kooi
Craig W. Vander Kooi
BBBrian M. Baker
Brian M. Baker
T cell receptors (TCRs) are key to antigen-specific immunity and are increasingly being explored as therapeutics, most visibly in cancer immunotherapy. As TCRs typically possess only low-to-moderate affinity for their peptide/MHC (pMHC) ligands, there is a recognized need to develop affinity-enhanced TCR variants. Previous in vitro engineering efforts have yielded remarkable improvements in TCR affinity, yet concerns exist about the maintenance of peptide specificity and the biological impacts of ultra-high affinity. As opposed to in vitro engineering, computational design can directly address these issues, in theory permitting the rational control of peptide specificity together with relatively controlled increments in affinity. Here we explored the efficacy of computational design with the clinically relevant TCR DMF5, which recognizes nonameric and decameric epitopes from the melanoma-associated Melan-A/MART-1 protein presented by the class I MHC HLA-A2. We tested multiple mutations selected by flexible and rigid modeling protocols, assessed impacts on affinity and specificity, and utilized the data to examine and improve algorithmic performance. We identified multiple mutations that improved binding affinity, and characterized the structure, affinity, and binding kinetics of a previously reported double mutant that exhibits an impressive 400-fold affinity improvement for the decameric pMHC ligand without detectable binding to non-cognate ligands. The structure of this high affinity mutant indicated very little conformational consequences and emphasized the high fidelity of our modeling procedure. Overall, our work showcases the capability of computational design to generate TCRs with improved pMHC affinities while explicitly accounting for peptide specificity, as well as its potential for generating TCRs with customized antigen targeting capabilities. T cell receptors (TCRs) play a major role in immunity, recognizing peptide antigens presented by major histocompatibility complex proteins. Due to their capacity to target intracellularly produced proteins and initiate cell killing, there is significant interest developing TCR-based therapeutic strategies, particularly towards cancer. A concern with TCRs is their weak-to-moderate affinities, which limits therapeutic potential. While in vitro evolution has been used to enhance TCR affinity, with sometimes spectacular results, these techniques can reduce peptide specificity and offer little control over affinity enhancements. Here we explored the use of structure-based computational design to enhance TCR affinity, which in principle can permit control over both specificity and affinity gains. We examined a clinically relevant TCR recently used in melanoma immunotherapy, identifying and characterizing mutations which enhanced affinity with no detectable impacts on binding specificity. We solved a crystal structure of our highest affinity designed TCR in complex with antigen, which indicated high accuracy of the structural modeling during the design process, and we critically evaluated several design protocols and functions to further improve design success. These results provide valuable insights into the use of computational design for TCRs. Lastly, the enhanced affinity variants identified may be of potential clinical benefit.

15 June 2012 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
WHWilliam F. Hawse
William F. Hawse
MCMatthew M. Champion
Matthew M. Champion
MJMichelle V. Joyce
Michelle V. Joyce
LHLance M. Hellman
Lance M. Hellman
MHMoushumi Hossain
Moushumi Hossain
BBBrian M. Baker
Brian M. Baker
T cells use the αβ TCR to bind peptides presented by MHC proteins (pMHC) on APCs. Formation of a TCR–pMHC complex initiates T cell signaling via a poorly understood process, potentially involving changes in oligomeric state, altered interactions with CD3 subunits, and mechanical stress. These mechanisms could be facilitated by binding-induced changes in the TCR, but the nature and extent of any such alterations are unclear. Using hydrogen/deuterium exchange, we demonstrate that ligation globally rigidifies the TCR, which via entropic and packing effects will promote associations with neighboring proteins and enhance the stability of existing complexes. TCR regions implicated in lateral associations and signaling are particularly affected. Computational modeling demonstrated a high degree of dynamic coupling between the TCR constant and variable domains that is dampened upon ligation. These results raise the possibility that TCR triggering could involve a dynamically driven, allosteric mechanism.

1 May 2016 in Journal of Immunological Methods
Verified
Journal Article
Closed access
LHLance M. Hellman
Lance M. Hellman
LYLiusong Yin
Liusong Yin
YWYuan Wang
Yuan Wang
SBSydney J. Blevins
Sydney J. Blevins
TRTimothy P. Riley
Timothy P. Riley
BBBrian M. Baker
Brian M. Baker

1 February 2019 in Molecular Therapy
Verified
Journal Article
Open access
LHLance M. Hellman
Lance M. Hellman
KFKendra C. Foley
Kendra C. Foley
NSNishant K. Singh
Nishant K. Singh
JAJesus A. Alonso
Jesus A. Alonso
TRTimothy P. Riley
Timothy P. Riley
BBBrian M. Baker
Brian M. Baker
T cell receptors (TCRs) have emerged as a new class of immunological therapeutics. However, though antigen specificity is a hallmark of adaptive immunity, TCRs themselves do not possess the high specificity of monoclonal antibodies. Although a necessary function of T cell biology, the resulting cross-reactivity presents a significant challenge for TCR-based therapeutic development, as it creates the potential for off-target recognition and immune toxicity. Efforts to enhance TCR specificity by mimicking the antibody maturation process and enhancing affinity can inadvertently exacerbate TCR cross-reactivity. Here we demonstrate this concern by showing that even peptide-targeted mutations in the TCR can introduce new reactivities against peptides that bear similarity to the original target. To counteract this, we explored a novel structure-guided approach for enhancing TCR specificity independent of affinity. Tested with the MART-1-specific TCR DMF5, our approach had a small but discernible impact on cross-reactivity toward MART-1 homologs yet was able to eliminate DMF5 cross-recognition of more divergent, unrelated epitopes. Our study provides a proof of principle for the use of advanced structure-guided design techniques for improving TCR specificity, and it suggests new ways forward for enhancing TCRs for therapeutic use.